{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:49:54Z","timestamp":1782604194484,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.577159","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T04:57:35Z","timestamp":1603688255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Eric A.","family":"Marvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley L.","family":"Furrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Cuoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/OTT.S235714","article-title":"Use of programmed death receptor-1 and\/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.21037\/atm.2018.10.27","article-title":"The risk factors for brain metastases in patients with non-small cell lung cancer","volume":"6","author":"Lim","year":"2018","journal-title":"Ann Transl Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer."},{"key":"B5","first-page":"4655","article-title":"Recent trends in epidemiology of brain metastases: an overview","volume":"32","author":"Tabouret","year":"2012","journal-title":"Anticancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CNS27","DOI":"10.2217\/cns-2018-0016","article-title":"Shifting paradigms: whole brain radiation therapy vs. stereotactic radiosurgery for brain metastases","volume":"8","author":"Shinde","year":"2019","journal-title":"CNS Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","article-title":"Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer","volume":"31","author":"Welsh","year":"2013","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18632\/oncotarget.763","article-title":"Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer","volume":"4","author":"Falchook","year":"2013","journal-title":"Oncotarget."},{"key":"B14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancel Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/1759-7714.12963","article-title":"Pembrolizumab for non-small cell lung cancer with central nervous system metastases: a two-case report","volume":"10","author":"Di","year":"2019","journal-title":"Thorac Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12885-018-5214-8","article-title":"Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nec.2010.08.007","article-title":"Epidemiology of metastatic brain tumors","volume":"22","author":"Fox","year":"2011","journal-title":"Neurosurg Clin N Am."},{"key":"B19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00280-009-1085-7","article-title":"Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates","volume":"65","author":"Jacobs","year":"2010","journal-title":"Cancer Chemother Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1172\/JCI0215451","article-title":"Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo","volume":"110","author":"Fellner","year":"2002","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/01.cad.0000136882.19552.8f","article-title":"Limited cerebrospinal fluid penetration of docetaxel","volume":"15","author":"ten Tije","year":"2004","journal-title":"Anticancer Drugs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s002800000253","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates","volume":"47","author":"Kerr","year":"2001","journal-title":"Cancer Chemother Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40262-015-0319-6","article-title":"Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature","volume":"55","author":"Jacus","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1358\/dot.2015.51.1.2250387","article-title":"Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer","volume":"51","author":"McDermott","year":"2015","journal-title":"Drugs Today."},{"key":"B25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.20892\/j.issn.2095-3941.2017.0086","article-title":"PD-1\/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy","volume":"15","author":"Jia","year":"2018","journal-title":"Cancer Biol Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e228917","DOI":"10.1136\/bcr-2018-228917","article-title":"Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab","volume":"12","author":"Lee","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/j.cllc.2019.06.002","article-title":"Durable response after 2 doses of pembrolizumab in a patient with non-small-cell lung cancer with an isolated brain metastasis","volume":"20","author":"Uprety","year":"2019","journal-title":"Clin Lung Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1007\/s12325-019-01057-7","article-title":"Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"36","author":"Incorvaia","year":"2019","journal-title":"Adv Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"s36","DOI":"10.1016\/j.ijrobp.2019.06.453","article-title":"Final results of a phase II prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"105","author":"Campbell","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0360-3016(98)00198-9","article-title":"Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases","volume":"42","author":"Agboola","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.577159\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T04:57:38Z","timestamp":1603688258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.577159\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":33,"alternative-id":["10.3389\/fonc.2020.577159"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.577159","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"article-number":"577159"}}